epidemiolog
virolog
evalu
combin
intervent
increas
hiv
diagnosi
among
men
sex
men
msm
curitiba
brazil
introduct
prior
studi
brazil
shown
group
men
sex
men
msm
sever
affect
hiv
multidisciplinari
team
launch
communitywid
intervent
citi
curitiba
evalu
accept
uptak
costeffect
multipl
hiv
test
servic
ht
current
studi
aim
evalu
hiv
test
coverag
among
msm
month
intervent
method
probabilist
sampl
men
select
curitiba
sampl
stratifi
place
resid
higher
select
probabl
area
greater
msm
concentr
question
histori
hiv
test
frequenc
test
last
month
place
result
last
test
well
knowledg
accept
expand
ht
made
result
proport
msm
total
sampl
hiv
test
coverag
least
lifetim
last
month
month
prior
interview
among
msm
proport
much
higher
respect
approxim
one
third
msm
alreadi
oral
fluid
test
time
higher
proport
greater
total
sampl
howev
msm
test
last
time
primari
care
servic
privat
servic
use
test
servic
provid
project
hiv
preval
among
men
test
least
lifetim
among
msm
preval
ratio
greater
result
indic
intervent
increas
hiv
diagnosi
substanti
expand
msm
access
hiv
test
month
implement
target
test
msm
curitiba
like
exceed
less
year
followup
msm
test
via
web
platform
servic
evalu
inform
program
improv
curitiba
facilit
expans
larger
brazilian
citi
introduct
though
percentag
hiv
posit
msm
low
among
regist
case
armenia
take
account
behavior
characterist
msm
prevent
hiv
among
group
popul
prioriti
armenia
prevent
program
msm
deliv
four
citi
armenia
msm
receiv
full
packag
servic
inform
hiv
provis
condom
lubric
counsel
test
hiv
aim
identifi
key
behavior
characterist
due
msm
acquir
hiv
level
knowledg
hiv
preval
hiv
method
studi
done
use
rd
method
among
msm
capitol
armeniayerevan
behavior
biolog
surveil
conduct
msm
answer
questionnair
year
blood
test
hiv
antibodi
done
knowledg
measur
answer
five
key
question
accord
guidelin
data
analyz
rdsat
method
studi
conduct
nation
center
aid
prevent
accord
nation
guidelin
approv
moh
armenia
preval
hiv
among
msm
knowledg
hiv
indic
condom
use
last
anal
sex
percentag
msm
use
condom
last
sex
casual
partner
percentag
msm
use
condom
last
one
year
conclus
preval
hiv
decreas
increas
knowledg
hiv
msm
still
practic
riski
behavior
need
continu
prevent
program
focus
transform
safe
sexual
behavior
increas
selfesteem
help
chang
attitud
toward
health
make
healthi
nonstigmat
environ
msm
feel
free
express
problem
receiv
adequ
solut
introduct
new
trend
perceiv
hiv
infect
reveal
grow
continu
adapt
pandem
recent
increas
particip
elderli
studi
claim
consequ
advanc
treatment
societi
age
hivposit
requir
know
understand
elderli
popul
live
infect
aim
analyz
profil
peopl
age
report
hiv
poor
state
northeastern
brazil
describ
characterist
associ
profil
methodolog
descript
epidemiolog
studi
conduct
databas
notifi
diseas
inform
system
sinannet
use
ministri
health
brazil
collect
process
data
notif
diseas
throughout
countri
data
collect
octob
relat
year
tabul
carri
simpl
descript
analysi
use
excel
result
report
case
hiv
infect
elderli
piaui
show
rapid
growth
year
especi
sinc
male
individu
still
correspond
largest
number
report
case
howev
upward
trend
infect
women
higher
frequenc
individu
incomplet
primari
educ
incomplet
colleg
educ
lowest
frequenc
among
infect
via
sexual
correspond
case
occur
primari
among
heterosexu
peopl
highest
number
case
peopl
declar
brown
male
still
correspond
report
case
hiv
categori
sexual
exposur
frequent
confirm
unprotect
sex
constitut
main
rout
transmiss
also
among
older
educ
consid
indic
measur
socioeconom
level
associ
popul
health
case
present
incomplet
elementari
school
year
studi
prospect
hiv
hbv
hcv
screen
cancer
center
emerg
depart
bruno
granwehr
kelli
merriman
richard
grime
zeena
shelal
hadil
bazerbashi
patricia
brock
carmen
gonzalez
harri
torr
terri
rice
univers
texa
md
anderson
cancer
center
houston
usa
introduct
recent
studi
hiv
test
among
patient
undergo
chemotherapi
center
show
hiv
test
rang
high
among
hodgkin
lymphoma
patient
low
among
cervic
cancer
patient
sought
determin
impact
routin
screen
hiv
cancer
patient
present
emerg
depart
ed
mani
previous
test
given
risk
reactiv
exacerb
hepat
b
hepat
c
cancer
treatment
implement
routin
screen
well
materi
method
implement
hiv
hepat
b
c
test
ed
larg
tertiari
cancer
center
approxim
patient
seen
annual
test
inform
obtain
use
bill
laboratori
databas
hiv
test
routin
implement
juli
hepat
b
c
test
ad
may
test
result
describ
result
test
rate
improv
consider
intervent
juli
august
newli
diagnos
patient
screen
posit
hiv
may
juli
addit
hepat
b
c
screen
demonstr
incid
newli
diagnos
hepat
b
hepat
c
seroposit
rate
respect
conclus
routin
hiv
test
feasibl
comprehens
cancer
center
ed
seropreval
hiv
hepat
b
hepat
c
virus
compar
noncanc
center
ed
result
demonstr
import
test
virus
potenti
cure
one
cancerassoci
viru
hepat
c
reduc
transmiss
anoth
cancerassoci
viru
hiv
long
term
goal
project
demonstr
feasibl
serv
model
routin
hiv
screen
among
cancer
popul
center
cancer
treat
facil
hivinfect
relateddetermin
amongst
clinic
attende
within
rural
urban
health
facil
cameroon
aim
studi
conduct
within
framework
nation
program
fight
hiv
aid
aim
assess
impact
hiv
infect
hospit
system
cameroon
studi
identifi
among
other
preval
hiv
among
patient
visit
public
privat
health
facil
well
behavior
materi
method
studi
conduct
within
quantit
transvers
studi
carri
administr
questionnair
patient
visit
health
facil
randomli
select
region
cameroon
data
enter
epidata
analyz
result
result
patient
reveal
overal
hiv
preval
among
patient
visit
health
facil
hiv
preval
higher
nation
preval
accord
studi
site
eastern
region
south
central
higher
preval
littor
north
west
south
west
lower
preval
sex
women
infect
preval
men
accord
age
patient
within
age
group
year
old
repres
hivposit
patient
hiv
preval
risk
hivposit
patient
twice
age
group
year
compar
age
group
year
risk
signific
compar
patient
within
age
group
age
older
conclus
rel
high
preval
hiv
patient
rel
increas
risk
infect
health
care
staff
health
caregiv
thu
repres
group
risk
group
target
intervent
fight
hiv
aid
care
taken
also
need
gener
hiv
screen
patient
visit
health
facil
dual
contracept
method
use
among
hiv
discord
coupl
zambia
kristin
wall
william
kilemb
bellington
vwalika
lisa
haddad
naw
htee
kh
ilen
brill
cheswa
vwalika
elwyn
chomba
amanda
tichacek
susan
allen
emori
univers
atlanta
usa
introduct
dual
method
use
condom
hiv
prevent
plu
effect
modern
contracept
method
unintend
pregnanc
prevent
public
health
prioriti
heterosexu
coupl
benefici
impact
primari
hiv
prevent
prevent
unintend
pregnanc
prevent
mothertochild
transmiss
via
unintend
pregnanc
prevent
howev
rate
dual
method
use
remain
low
improv
understand
factor
predict
use
need
method
heterosexu
zambian
coupl
mfand
mf
enrol
longitudin
followup
coupl
censor
pregnanc
outcom
interest
timevari
dual
method
use
defin
indic
unprotect
sex
selfreport
unprotect
sex
sperm
vagin
swab
wet
prep
incid
pregnanc
incid
trichomoniasi
incid
hiv
seroconvers
plu
use
modern
contracept
method
implant
inject
intrauterin
devic
oral
contracept
pill
perman
method
multivari
repeat
outcom
surviv
analysi
model
accommod
fix
timevari
covari
andersongil
model
explor
factor
associ
dual
method
use
result
coupl
follow
averag
two
year
dual
method
use
document
studi
interv
multivari
analys
factor
strongli
associ
nondual
method
use
women
postpartum
versu
pregnant
adjust
hazard
ratio
ci
even
control
fertil
intent
conclus
postpartum
women
may
import
group
advoc
dual
method
use
expect
increas
fertil
intent
associ
use
dual
method
expand
promot
safe
concept
approach
urgent
need
discord
coupl
pragmat
achiev
integr
cvct
coupl
famili
plan
servic
qualiti
life
assess
peopl
live
without
hiv
upbeat
studi
background
hrqol
previous
found
impair
peopl
live
hiv
plwh
increasingli
contribut
evolv
polici
around
manag
plwh
aim
explor
differ
predictor
hrqol
hivposit
hiv
hivneg
hiv
subject
method
hrqol
moshiv
assess
studi
entri
week
hiv
upbeat
studi
prospect
cohort
hiv
hivsubject
similar
demograph
background
respons
summar
overal
hrqol
plu
compon
summari
score
physic
pc
mental
health
mc
higher
score
indic
better
health
sociodemograph
clinic
data
includ
bone
miner
densiti
bmd
assess
obtain
visit
comparison
group
assess
use
mannwhitney
student
test
chisquar
test
multivari
linear
regress
model
explor
factor
associ
hrqol
result
total
subject
hiv
complet
hrqol
assess
includ
analysi
hiv
poorer
socioeconom
statu
hiv
level
educ
vs
household
incom
conclus
hiv
smoke
relat
poorer
hrqol
across
compon
social
variabl
mainli
impact
msc
clinic
variabl
affect
psc
male
patient
femal
idu
femal
patient
men
infect
sexual
contact
phylogenet
analysi
dna
fragment
show
patient
subtyp
b
subtyp
c
subtyp
case
g
urf
determin
conclus
thu
us
shown
territori
republ
belaru
subtyp
case
infect
share
continu
domin
introduct
biolog
product
use
human
raw
materi
product
high
probabl
transmiss
infecti
agent
among
virus
studi
viral
marker
one
recommend
safeti
measur
control
lot
product
question
though
disput
unavail
mean
specif
diagnos
use
mani
countri
cuba
lisida
appoint
qualiti
control
lot
hemoderiv
biolog
use
algorithm
work
includ
serolog
molecular
techniqu
studi
viral
marker
human
immunodefici
viru
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
aim
studi
show
result
use
algorithm
use
lisida
final
approv
product
materi
method
total
lot
product
studi
activ
pharmaceut
ingredi
api
human
albumin
intermedi
product
total
specif
immunoglobulin
bulk
final
immunoglobulin
product
intraven
intramuscular
use
dialyz
leukocyt
extract
transfer
factor
chorion
gonadotropin
follow
methodolog
propos
laboratori
detect
antibodi
hiv
hcv
hbv
surfac
antigen
polymeras
chain
reaction
hiv
hcv
result
lot
approv
except
api
hemoderiv
bulk
specif
immunoglobulin
reactiv
hcv
well
lot
dialyz
leukocyt
extract
transfer
factor
posit
pcr
hepat
c
reactiv
detect
stage
allow
stop
product
process
conclus
algorithm
work
qualiti
control
lot
hemoderiv
product
risk
viral
contamin
prove
use
tool
certif
process
visual
hiv
vagin
mucos
transmiss
pathway
use
vivo
imag
also
exhibit
addit
synergist
effect
activ
combin
numer
approv
antivir
drug
pbmc
pretreat
increas
cellular
activ
marker
induc
inflammatori
cytokineschemokin
extend
studi
virus
show
inhibit
replic
denv
serotyp
rajidcsign
rajilsign
human
dendrit
cell
low
rang
timeofdrug
addit
studi
reveal
act
viral
entri
also
inhibit
highli
contagi
airborn
pathogen
orthomyxoviru
strain
influenza
viru
eg
subtyp
influenza
b
strain
pneumoviru
respiratori
syncyti
viru
rsv
deciph
uniqu
mechan
antivir
activ
ongo
conclus
labyrinthopeptin
prototyp
peptid
novel
class
carbacycl
lantibiot
broadspectrum
antivir
activ
db
use
determin
viral
load
resist
vietnames
hiv
patient
viral
load
measur
gener
hiv
viral
load
biocentr
reproduc
repeat
assess
order
test
real
work
condit
db
made
hospit
patient
carri
saintpaul
hospit
hanoi
test
perform
parallel
db
made
saintpaul
hospit
patient
resist
associ
mutat
determin
treat
patient
use
anr
protocol
test
viral
load
resist
mutat
detect
conduct
parallel
plasma
db
result
viral
load
copiesml
plasma
db
quantif
obtain
sampl
plasma
db
pb
buffer
gave
better
result
elut
avl
buffer
qiagen
best
result
obtain
blood
elut
volum
respect
reproduct
repeat
better
condit
imposs
obtain
rt
sequenc
one
db
two
sampl
differ
resist
profil
observ
db
plasma
conclus
author
suggest
whole
blood
provir
dna
presenc
could
result
viral
load
overquantif
interestingli
observ
overquantif
compar
plasma
valu
howev
result
obtain
viral
resist
detect
less
satisfactori
differ
may
due
provir
dna
sequenc
select
resist
substitut
dtg
caus
diminish
integr
explain
lack
clinic
signific
drug
resist
compound
introduct
object
commun
user
period
promot
chang
behavior
conduc
health
creat
question
reflect
exchang
theme
hivaid
time
becom
awar
risk
involv
time
strong
emot
also
reach
chang
collect
represent
neg
behavior
relat
hiv
transmiss
use
condom
casual
sex
exampl
whatev
happen
effect
treatment
exist
materi
method
identifi
dozen
parti
locat
citi
kribi
obtain
agreement
oper
facilit
work
volunt
train
coordin
fifti
volunt
includ
ten
supervisor
mobil
site
mandatori
twoday
train
volunt
essenti
main
theme
address
commun
attitud
strategi
adopt
volunt
site
differ
configur
focu
prevent
incent
test
screen
stigma
mission
coordin
supervisor
place
dj
disc
jockey
present
encourag
get
messag
even
entri
artist
stage
use
slogan
messag
appear
leaflet
postcard
produc
structur
struggl
aid
train
volunt
task
invit
user
particip
address
briefli
bulk
theme
distribut
materi
condom
affix
poster
strateg
locat
therefor
issu
presenc
place
life
remind
user
simpli
legitimaci
fun
fun
preserv
health
result
februari
sever
action
plan
peopl
expos
messag
conclus
despit
differ
configur
locat
life
conduc
promot
health
evalu
peer
base
intervent
kap
medic
student
toward
hiv
eight
medic
school
cairo
descript
studi
ahm
moham
tammam
abdelgawad
american
univers
cairo
egypt
hiv
educ
vital
among
young
peopl
start
medic
career
erad
stigma
discrimin
health
provid
studi
object
evalu
effect
peer
educ
program
knowledg
attitud
behavior
relat
hiv
among
medic
scienc
student
cairo
kap
survey
administ
among
student
method
colleg
medic
background
medicin
pharmaci
dentistri
scienc
alazhar
univers
use
stratifi
cluster
sampl
femal
age
rang
averag
period
week
follow
three
month
school
base
peer
educ
program
post
assess
evalu
chang
paramet
knowledg
hiv
way
transmiss
access
hiv
test
health
servic
provid
attitud
toward
plhiv
data
collect
medic
student
ethic
approv
analyz
use
spss
baselin
identifi
least
three
way
hiv
transmiss
show
offend
emot
reaction
toward
plhiv
express
approv
provid
medic
servic
plhiv
reason
due
link
hiv
forbidden
sexual
practic
also
fear
transmiss
awar
campaign
identifi
least
three
way
hiv
transmiss
attitud
toward
plhiv
improv
offend
emot
reaction
toward
plhiv
becom
express
approv
provid
medic
servic
school
base
educ
medic
student
effect
tool
enhanc
hiv
knowledg
improv
futur
medic
profess
attitud
toward
plhiv
medic
curricula
sensit
medic
staff
student
activ
particip
battl
aid
characterist
hiv
test
determin
knowledg
hiv
statu
south
africa
conclus
educ
hiv
aid
particular
men
younger
age
group
need
improv
order
enhanc
uptak
hct
qualiti
hiv
counsel
need
assess
signific
proport
respond
receiv
either
preor
posttest
counsel
infant
immun
visit
entri
identifi
follow
hiv
expos
infant
uniqu
chanc
offer
hiv
test
nurs
women
miss
opportun
offer
intervent
motherinf
pair
object
integr
immun
hiv
servic
ensur
women
miss
hiv
test
offer
test
posit
motherinf
pair
receiv
intervent
per
guidelin
method
total
facil
select
eight
district
mara
region
lake
zone
tanzania
two
staff
per
facil
orient
identif
women
miss
hiv
test
counsel
hiv
test
appropri
intervent
referr
motherinf
district
health
team
also
involv
advocaci
supervis
ensur
sustain
quarterli
visit
done
supervis
data
collect
result
data
analyz
ten
facil
select
conveni
januari
june
assess
progress
util
intervent
infant
age
week
seen
period
unknown
statu
mother
test
hiv
pregnanc
hiv
counsel
test
offer
nurs
mother
found
hiv
refer
ctc
care
treatment
infant
receiv
hiv
dna
pcr
test
intervent
per
standard
care
conclus
routin
immun
visit
offer
uniqu
opportun
hiv
test
specif
intervent
motherinf
pair
miss
opportun
pregnanc
region
district
team
support
roll
integr
gap
implement
pmtct
program
mogwas
health
center
result
analysi
hivexpos
babi
born
within
given
period
pcr
test
test
posit
shown
figur
babi
retest
age
rapid
test
one
babi
transfer
anoth
clinic
test
posit
conclus
base
result
number
new
hiv
infect
age
group
significantli
reduc
rural
set
south
africa
effect
implement
pmtct
program
proper
anc
manag
play
crucial
role
prevent
hiv
motherto
child
transmiss
thu
import
encourag
earli
anc
book
exclus
breastfeed
till
age
month
well
improv
referr
system
monitor
record
movement
patient
amongst
health
institut
much
attent
paid
arv
initi
hivposit
motherstob
test
hivexpos
babi
encourag
rapid
retest
children
age
month
introduct
compar
group
key
popul
share
import
burden
aid
lack
data
risk
face
locat
challeng
relat
contact
fill
variou
integr
effort
epidemiolog
profil
implement
unaid
object
review
statu
key
group
bujumbura
methodolog
visit
organ
civil
societi
work
directli
group
make
interview
offici
consult
work
tool
registri
organ
field
visit
possibl
meet
peer
educ
make
mainten
session
find
war
affect
popular
quarter
live
major
sex
worker
men
sex
men
respect
estim
seropreval
live
capit
accord
data
studi
place
problem
revis
plan
strategi
oper
one
great
obstacl
past
come
absenc
recent
survey
nonexist
recent
result
imposs
make
updat
classic
result
studi
research
one
year
war
survey
show
theoret
issu
follow
crisi
countri
coverag
key
popul
alter
impact
hardli
evalu
estim
departur
categori
peopl
precis
known
sadli
see
refug
citi
foreign
countri
goe
beyond
mere
mobil
back
forth
day
conclus
risk
factor
stigma
lack
access
inform
servic
increas
addit
fear
go
street
affect
intervent
commun
compon
peer
educ
condom
gel
distribut
commun
organ
attract
activ
around
convivi
center
result
repres
ten
children
two
consecut
pregnanc
mother
three
children
triplet
pregnanc
anoth
mother
seven
mother
low
social
statu
educ
belong
transmiss
categori
ivdu
intraven
drug
user
two
prostitut
mother
coinfect
hivhcv
two
infect
third
viral
infect
hbv
two
mother
data
latent
tuberculosi
infect
posit
quantiferon
test
mother
poor
adher
followup
therefor
fail
appear
start
antiretrovir
treatment
pregnanc
among
case
two
complet
maternalfet
transmiss
pregnanc
end
vertic
transmiss
infect
mother
third
stage
hivinfect
sever
immun
suppress
high
viral
load
hiv
describ
group
mother
third
stage
hivinfect
infant
born
prematur
reduc
weight
gain
sinc
monitor
children
hospit
third
month
birth
could
explicit
infect
hcv
follow
interrupt
four
children
clinic
manifest
withdraw
symptom
due
drug
addict
mother
children
observ
moder
intrapart
asphyxia
retent
weight
gain
laboratori
studi
eight
children
establish
anemia
five
children
thrombocytosi
may
indic
infecti
process
valu
platelet
rang
gl
averag
blood
studi
liver
enzym
creatinin
urea
blood
glucos
establish
abnorm
even
children
abstin
syndrom
substitut
therapi
microbiolog
studi
three
children
throat
swab
isol
bacteri
agent
staphilococcu
aureu
klebsiella
pneumonia
pseudomona
aeruginosa
held
antibacteri
therapi
journal
viru
erad
supplement
conclus
social
factor
major
limit
maternalfet
transmiss
hivinfect
also
viral
infect
even
known
case
hiv
possibl
prevent
vertic
transmiss
remain
difficult
appli
risk
group
women
intraven
drug
user
sex
worker
poor
social
statu
accord
law
bulgaria
health
inform
associ
hivstatu
person
disclos
without
express
written
consent
sens
even
women
establish
hivinfect
could
give
birth
without
data
becom
known
relev
medic
team
matern
depart
also
remain
voluntari
hivtest
pregnanc
creat
prerequisit
spread
infect
high
preval
late
diagnosi
hiv
eastern
algeria
haart
era
object
delay
diagnosi
hiv
infect
common
problem
lead
increas
hiv
relat
morbid
mortal
healthcar
cost
poor
outcom
aim
studi
evalu
preval
epidemiolog
clinic
characterist
determin
risk
factor
associ
late
present
lp
method
retrospect
studi
conduct
referr
hospit
setif
citi
east
algeria
januari
decemb
age
gender
stage
present
hiv
viral
load
upon
diagnosi
outcom
collect
lp
defin
present
care
aidsdefin
event
regardless
cell
count
result
naiv
patient
includ
studi
lp
diagnos
first
time
patient
male
heterosexu
mean
age
year
rang
year
lp
vari
among
gender
age
group
transmiss
rout
found
signific
associ
heterosexu
transmiss
rout
p
age
group
year
lp
median
hiv
viral
load
copiesml
lp
requir
art
within
month
diagnosi
lp
pulmonari
extrapulmonari
tuberculosi
event
manag
tuberculosi
challeng
due
addit
drug
toxic
interact
patient
die
die
within
month
diagnosi
conclus
fraction
lp
high
impact
art
effect
lower
surviv
probabl
polici
hivprevent
algeria
need
includ
aggress
strategi
test
diagnos
treat
hiv
infect
earli
possibl
thu
spread
diseas
treatment
cost
decreas
amandin
gagneuxbrunon
elisabeth
botelhonev
olivi
morann
pierr
delanay
christoph
mariat
ann
fresard
lucht
saintetienn
univers
hospit
saintetienn
franc
background
glomerular
filtrat
rate
gfr
regularli
evalu
hivinfect
patient
chronic
kidney
diseas
ckd
highli
preval
popul
equat
develop
chronic
kidney
epidemiolog
collabor
group
ckdepi
recommend
popul
howev
perform
ckdepi
hivinfect
patient
affect
age
true
gfr
aim
evalu
interest
direct
measur
gfr
plasmat
iohexol
clearanc
hiv
infect
patient
method
gfr
measur
mgfr
singlecent
cohort
hivinfect
patient
plasma
iohexol
clearanc
inject
ml
iohexol
iohexol
dosag
min
plasma
gfr
estim
ckdepi
studi
equat
creatinin
dosag
idmstrac
iohexol
concentr
measur
hplcm
albuminuria
evalu
albuminuria
creatininuria
ratio
acr
result
gfr
measur
particip
mean
mean
mgfr
receiv
haart
nineteen
patient
mgfr
among
patient
low
gfr
identifi
use
ckdepi
undiagnos
patient
ckdepi
signific
albuminuria
urinari
creatinin
acr
may
help
clinician
identifi
risk
patient
accord
ckd
classif
kidney
diseas
improv
global
outcom
guidelin
kdigo
patient
low
mgfr
significantli
older
other
patient
vs
p
identifi
factor
associ
misdiagnosi
ckdepi
mean
bia
ckdepi
patient
low
gfr
gfr
overestim
patient
overestim
rang
observ
side
effect
relat
iohexol
inject
use
gfr
measur
acr
patient
identifi
atrisk
accord
kdigo
classif
conclus
mgfr
use
accept
way
diagnos
ckd
hivinfect
patient
particularli
older
patient
reduct
gfr
may
sign
ckd
gfr
estim
often
overestim
mgfr
hiv
infect
annual
synthesi
report
experi
dermatolog
depart
saint
joseph
hospit
marseil
franc
declin
prior
diagnosi
hepatocarcinoma
hivinfect
patient
new
predictor
aim
declin
observ
case
cancer
hivinfect
patient
hepatocarcinoma
hcc
frequent
seroposit
patient
prognosi
depend
earli
diagnosi
describ
cours
cell
count
ratio
prior
hcc
diagnosi
hivinfect
patient
materi
method
retrospect
studi
perform
outpati
clinic
receiv
nearli
thousand
hivinfect
peopl
hcvcoinfect
patient
diagnos
hcc
select
hiv
viral
load
vl
cell
count
ratio
preced
hcc
diagnosi
baselin
bl
collect
patient
characterist
describ
bl
result
hcc
pt
male
median
age
identifi
bl
median
hiv
followup
cart
median
exposur
undetect
hivvl
hcvcoinfect
neg
hcvrna
median
count
mm
mm
respect
four
patient
expos
ifn
exclud
median
cell
count
ratio
bl
shown
figur
studi
aim
assess
cardiovascular
risk
plwha
accord
framingham
score
identifi
associ
risk
demograph
behavior
psychosoci
clinic
variabl
cross
section
studi
data
collect
use
sociodemograph
clinic
behavior
questionnair
assess
healthi
eat
lipp
inventori
sympton
stress
adult
framingham
score
data
analysi
carri
descript
statist
chisquar
test
p
male
age
year
white
observ
sedentari
smoker
symptom
stress
resist
exhaust
phase
respect
respect
gener
clinic
famili
histori
hypertens
dm
ami
stroke
person
histori
hypertens
diabet
dyslipidemia
also
bmi
greater
sup
sup
metabol
syndrom
regard
clinic
variabl
relat
hiv
diagnosi
hiv
use
haart
ten
year
respect
background
tobacco
increas
risk
type
diabet
atherosclerot
coronari
vascular
diseas
hip
fractur
cancer
one
common
driver
morbid
immun
activ
newli
appreci
contribut
neutrophil
immun
activ
particularli
interact
adapt
immun
cell
led
us
hypothes
smoke
fuel
neutrophil
activ
peopl
live
hiv
plhiv
aim
test
influenc
tobacco
use
level
neutrophil
activ
plhiv
method
sixtyseven
hiv
infect
adult
year
age
suppress
art
least
month
enrol
substudi
activih
studi
among
current
smoker
former
smoker
activ
evalu
flow
cytometri
surfac
neutrophil
express
find
mean
durat
viral
suppress
hiv
rna
plasma
copiesml
year
mean
count
cell
per
observ
smoker
present
higher
neutrophil
surfac
express
nonsmok
figur
moreov
link
daili
smoke
rate
cumul
tobacco
consumpt
neutrophil
surfac
densiti
current
smoker
discuss
smoke
associ
higher
number
circul
neutrophil
compar
nonsmok
data
establish
addit
increas
neutrophil
peripher
count
tobacco
smoke
correl
increas
membran
express
neutrophil
role
play
neutrophil
variou
immun
respons
consid
essenti
addit
old
view
neutrophil
first
immun
respond
cell
seem
involv
pathogenesi
variou
diseas
atherothrombosi
cancer
thu
tobacco
must
consid
neutrophil
activ
consumpt
might
fuel
chronic
neutrophil
activationmedi
morbid
comparison
virolog
host
hla
characterist
kenyan
children
rapid
slow
diseas
progress
ten
nef
function
domain
region
show
significantli
greater
variat
rp
sp
gag
sequenc
significantli
differ
group
report
protect
hlaa
allel
commonli
observ
sp
rp
wherea
reportedli
diseas
suscept
hlab
common
rp
sp
compar
rp
sp
show
significantli
higher
median
number
predict
hlabrel
epitop
nef
vs
hlabrel
epitop
gag
vs
hlaarel
epitop
gag
vs
sp
also
fewer
hlacrel
epitop
nef
median
vs
hlacrel
epitop
gag
median
vs
rp
conclus
compar
rapid
progressor
slow
progressor
protect
hlaa
allel
hlabrel
epitop
nef
gag
protein
result
suggest
host
factor
hla
play
stronger
role
diseas
progress
viral
factor
eg
nef
gag
variat
kenyan
children
hcv
coinfect
stimul
differenti
effector
tregulatori
cell
hiv
patient
subject
cart
kaposi
sarcoma
commonest
malign
other
adc
primari
cerebr
lymphoma
nonhodgkin
lymphoma
seen
one
patient
note
absenc
cervic
carcinoma
non
adc
lung
cancer
hodgkin
lymphoma
cutan
anaplast
lymphoma
testicular
plastocytoma
myeloid
leukemia
patient
mean
hiv
viral
load
copiesml
total
death
attribut
malign
mean
overal
surviv
malign
diagnosi
month
averag
durat
cart
malign
diagnosi
patient
die
equal
month
result
control
stent
posit
appli
esophagographi
comput
tomographi
patient
receiv
treatment
tb
drug
hiv
therapi
close
fistula
happen
monthsstent
taken
patient
method
effect
fistula
close
stent
taken
patient
method
effect
could
reach
close
fistula
surgic
treatment
use
factor
associ
mortal
aid
patient
cryptococc
mening
case
control
studi
introduct
solid
organ
transplant
occur
hiv
popul
includ
women
favor
outcom
still
littl
inform
pregnanc
outcom
set
awar
report
regard
complex
obstetr
medic
manag
twin
pregnanc
context
hiv
liver
transplant
describ
success
outcom
mdt
hiv
posit
femal
recipi
liver
transplant
twin
pregnanc
receiv
art
immunosuppress
therapi
casereport
patient
diagnos
hiv
posit
anoth
hospit
england
truvada
efavirenz
develop
subacut
liver
failur
secondari
art
toxic
receiv
emerg
liver
transplant
august
royal
free
hospit
london
switch
raltegravirbas
regimen
initi
tacrolimu
azathioprin
prednisolon
posttranspl
five
month
later
conceiv
natur
twin
pregnanc
undetect
arv
regimen
pregnanc
manag
multidisciplinari
team
includ
hiv
physician
obstetrician
midwiv
liver
specialist
increas
liver
function
test
lft
week
gestat
age
motiv
liver
biopsi
delay
week
exclud
reject
increas
lft
week
gestat
patient
remain
undetect
point
view
hiv
infect
howev
develop
high
bp
increas
creatinin
motiv
lower
segment
caesarean
section
week
gestat
gave
birth
two
healthi
hivneg
infant
birth
weight
twin
g
twin
g
conclus
manag
mdt
rapid
intervent
prevent
sever
complic
twin
pregnanc
hiv
posit
liver
transplant
recipi
favor
outcom
evid
introduct
persist
hepat
c
hiv
epidem
well
recurr
outbreak
dengu
denv
west
nile
wnv
fever
europ
emphas
import
prompt
countermeasur
reduc
fatal
limit
viral
spread
avail
antivir
limit
spectrum
efficaci
develop
broadspectrum
antivir
agent
repres
therefor
urgent
need
human
atpaserna
helicas
involv
replic
mani
viral
pathogen
target
host
factor
may
thu
repres
strategi
develop
broadspectrum
antivir
limit
emerg
viral
resist
materi
method
silico
drug
design
chemic
synthesi
enzymat
inhibitori
assay
use
identifi
activ
lead
infectedcel
base
assay
use
valid
antivir
activ
result
identifi
first
smallmolecul
nonnucleosid
inhibitor
rna
bind
site
helicas
broad
spectrum
antivir
activ
wild
type
hiv
drugresist
strain
hcv
denv
wnv
good
toxic
profil
suggest
activ
essenti
virus
could
dispens
cell
valid
pharmaceut
target
conclus
result
suggest
inhibitor
exploit
order
treat
hivhcv
coinfect
emerg
infecti
diseas
dengu
west
nile
patient
carri
drug
resist
strain
three
medic
condit
current
repres
major
challeng
clinic
treatment
result
overal
preval
tdr
nucleosid
revers
transcriptas
inhibitor
nrti
nonnucleosid
inhibitor
nnrti
proteas
inhibitor
pi
thymidin
associ
mutat
tam
preval
tdr
mutat
found
rt
gene
follow
revert
pi
associ
mutat
frequent
follow
subtyp
b
preval
follow
bf
recombin
subtyp
c
addit
subtyp
g
df
recombin
identifi
one
subject
conclus
increas
level
tdr
mutat
associ
nrti
nnrti
observ
time
trend
observ
seem
reflect
chang
antiretrovir
therapi
brazil
time
preval
pi
associ
tdr
mutat
gener
low
subtyp
b
preval
studi
identif
nonb
recombin
infect
suggest
recent
introduct
spread
virus
respect
africa
south
brazil
rio
de
janeiro
result
add
bodi
evid
support
recent
inclus
baselin
genotyp
pregnant
women
brazil
optim
treatment
reduc
risk
vertic
sexual
transmiss
carri
resist
strain
effect
late
report
haart
mortal
among
pregnant
women
rural
urban
malawi
clinic
provid
free
art
food
supplement
pregnant
women
hiv
posit
requir
treatment
women
start
haart
late
time
ci
risk
die
compar
women
start
haart
earli
pregnant
women
initi
haart
viral
load
less
hiv
rna
copiesml
time
ci
risk
die
women
lower
viral
load
conclus
studi
shown
evid
import
start
art
earli
among
pregnant
women
commun
haart
program
strengthen
health
educ
import
vct
earli
start
art
order
reduc
hivaid
mortal
morbid
among
pregnant
women
descript
analyt
crosssect
studi
preval
stage
chronic
kidney
diseas
ckd
among
tdf
user
hiv
posit
pregnant
lactat
mother
north
east
amhara
ethiopia
eyob
gebrehawariat
gebretsadik
getahun
asr
moham
hussien
world
health
organ
addi
ababa
ethiopia
introduct
increas
incid
fanconi
proxim
kidney
tubular
damag
declin
gfr
among
tdf
user
underli
renal
diseas
risk
factor
among
pregnant
drawn
clinician
attent
monitor
tdf
initi
follow
nation
kidney
associ
usnki
consid
ckd
less
bsa
current
practic
toxic
monitor
tdf
hospit
conduct
routin
aim
studi
aim
measur
preval
stage
renal
diseas
stage
crcl
gfrcg
chronic
kidney
diseas
ckd
among
tdf
base
haart
user
pregnant
lactat
women
factor
associ
declin
gfr
method
non
proport
probabl
sampl
total
pregnant
lactat
respect
zonal
hospit
eastern
amhara
activ
follow
pmtct
option
b
program
june
june
particip
studi
anthropometr
measur
data
collect
base
standard
procedur
nutrit
assess
height
weight
serum
creatinin
measur
hospit
laboratori
accredit
star
ephi
use
medicalc
android
applic
gfrcg
calcul
subject
classifi
nkf
kdoqi
classif
descript
analyt
statist
done
use
softwar
spss
version
aor
associ
factor
crosstab
conclus
preval
stage
mild
form
renal
diseas
among
tdf
base
haart
user
pregnant
lactat
mother
high
method
gfrcg
underestim
earli
detect
prevent
factor
bmi
less
stage
count
greater
significantli
associ
need
close
laboratori
monitor
stage
ckd
significantli
associ
among
baselin
stage
among
lactat
women
need
analysi
larger
sampl
size
studi
intraderm
inject
tat
result
major
particip
report
share
arv
hivneg
friendssex
partner
use
hiv
prevent
onethird
men
describ
sell
arv
pill
brokersdeal
sold
arv
hivneg
msm
sold
arv
msm
combin
drug
eg
methamphetamin
arv
includ
combin
tenofovir
disoproxil
fumar
emtricitabin
ingredi
use
prep
highli
valu
inform
market
arv
gener
particip
describ
feel
good
provid
arv
hivneg
men
believ
could
help
men
becom
hiv
infect
particip
includ
employ
within
local
hiv
su
facil
relev
posit
titl
minimum
one
year
relev
experi
idi
minut
follow
semistructur
guid
facilit
licens
clinic
psychologist
data
analyz
use
themat
analysi
iter
process
formal
analysi
confirm
preliminari
find
conduct
use
nvivo
result
theme
support
differenti
disson
found
provid
recogn
need
promot
coordin
care
versu
care
continuum
oper
studi
result
identifi
breakdown
care
coordin
occur
throughout
treatment
cascad
among
hivinfect
pwud
conceptu
model
present
identifi
patient
provid
systemlevel
barrier
facilit
within
care
coordin
process
conclus
result
highlight
challeng
among
hiv
su
provid
coordin
care
highrisk
popul
type
provid
hiv
su
lack
understand
treatment
modal
commun
process
provid
role
outsid
domain
expertis
systemand
providerlevel
intervent
strategi
util
facilit
linkag
retent
dual
care
servic
discuss
effect
gender
parent
death
school
educ
hivinfect
children
analysi
nepali
ngo
patient
background
hivposit
children
attend
school
studi
analyz
gender
parent
death
factor
influenc
school
educ
hivinfect
children
goal
convey
find
increas
school
educ
children
method
studi
analyz
ninetyfour
hivposit
children
treat
setu
nepal
collect
data
includ
gender
age
school
attend
parent
death
data
compil
compar
enrol
amongst
group
result
studi
particip
boy
girl
attend
school
boy
parent
live
enrol
school
compar
girl
parent
live
enrol
school
highest
enrol
amongst
girl
one
parent
live
boy
parent
deceas
enrol
rate
girl
rate
conclus
hivinfect
boy
parent
live
like
attend
school
possibl
due
stabl
famili
incom
enabl
prefer
son
attend
school
girl
one
live
parent
enrol
higher
rate
suggest
parent
death
may
releas
societi
poor
belief
femal
educ
boy
higher
enrol
girl
consist
nepal
gender
view
limit
studi
suggest
need
broader
studi
futur
research
examin
enrol
gap
girl
boy
parent
deceas
use
commerci
rectal
lubric
among
msm
lesson
rectal
microbicid
introduct
research
underway
develop
rectal
microbicid
gel
prevent
hiv
transmiss
studi
extent
mode
use
commerci
sexual
lubric
potenti
behavior
facilit
futur
use
rectal
microbicid
method
msm
age
year
report
condomless
recept
anal
intercours
rai
prior
year
enrol
pittsburgh
pa
boston
san
juan
pr
usa
respond
comput
assist
self
interview
lubric
use
rai
prior
three
month
result
particip
msm
mean
year
age
fiftyeight
percent
use
commerci
sexual
lubric
alway
sometim
among
lubric
user
use
waterbas
lubric
use
two
three
teaspoon
lubric
appli
around
anu
partner
peni
insid
rectum
partner
sex
reappli
lubric
twice
rai
particip
obtain
lubric
mainli
pharmaci
sex
shop
transpar
product
flavor
scent
prefer
prefer
somewhat
liquid
somewhat
thick
neither
ask
ideal
dispens
prefer
tube
like
toothpast
pump
contain
popup
lid
want
singl
use
dispos
tube
conclus
although
use
rectal
lubric
widespread
frequent
among
young
msm
use
need
boost
rectal
microbicid
gel
effect
report
use
lube
less
alway
transpar
flavorless
product
could
good
accept
least
two
differ
viscos
appear
necessari
limit
interest
lubric
deliv
dispos
tube
case
microbicid
gel
studi
lubric
applic
reapplic
frequent
carri
insert
recept
partner
may
support
microbicid
use
either
methodolog
estim
drug
cost
earli
antiretrovir
treatment
method
estim
addit
cost
earli
treatment
first
assum
delay
treatment
group
treat
three
year
studi
howev
delay
group
receiv
art
studi
end
portion
group
time
art
reduc
year
averag
wholesal
price
usa
recommend
art
regimen
discount
reflect
actual
price
result
averag
cost
us
per
person
per
year
usa
cost
would
treat
year
treat
year
data
use
estim
cost
per
patient
variou
cost
price
use
formula
local
cost
aloc
drug
cost
three
year
estim
cost
per
patient
calcul
drug
cost
per
year
result
rang
year
patient
patient
conclus
earli
treatment
consider
cost
futur
analys
consid
cost
save
avoid
seriou
clinic
event
reduct
transmiss
hiv
earli
treatment
issu
long
term
adher
receiv
art
greater
count
econom
impact
arv
treatment
person
live
hiv
household
member
koami
hodor
didier
amedegnato
action
contr
le
sida
ac
lome
togo
introduct
malnutrit
human
immunodefici
viru
hiv
infect
individu
associ
faster
diseas
progress
higher
mortal
rate
suboptim
respons
antiretrovir
therapi
art
due
fact
hiv
infect
mainli
adult
sexual
activ
year
inevit
fatal
socioeconom
implic
develop
immens
regard
three
kind
impact
distinguish
first
one
loss
incom
household
product
famili
member
particular
hesh
breadwinn
second
impact
increas
household
expenditur
cover
medic
cost
third
impact
indirect
cost
result
absente
member
famili
school
work
take
care
patient
method
studi
longitudin
survey
among
household
person
live
hiv
aid
household
gener
popul
involv
three
phase
five
six
region
togo
total
household
consist
case
control
household
interview
result
plwha
record
mean
bodi
mass
index
famili
control
difficulti
pay
school
expens
ward
observ
case
household
compar
control
household
due
difficulti
pay
school
expens
household
children
miss
school
inadequaci
resourc
children
case
household
result
total
studi
select
studi
recent
publish
gener
trend
among
msm
use
meet
applic
way
reach
rapid
free
prejudic
sexual
satisfact
men
like
engag
unprotect
anal
sex
chemsex
seri
casual
sex
partner
low
test
preval
popul
contrast
high
exposur
conclus
use
meet
applic
base
geoloc
msm
increas
exposur
individu
hiv
infect
enabl
individu
quick
casual
without
commit
sex
besid
high
rotat
partner
studi
necessari
elucid
behavior
order
enabl
prepar
promot
prevent
strategi
suit
individu
evalu
efficaci
hepat
b
vaccin
differ
age
group
vaccin
children
egypt
ahm
moham
tammam
abdelgawad
abdelmoneam
hosni
alazhar
univers
cairo
egypt
hbv
estim
infect
million
peopl
throughout
world
infect
infant
young
children
hepat
b
viru
repres
import
health
hazard
chronic
liver
diseas
subsequ
develop
cirrhosi
hepatocellular
carcinoma
hepat
b
vaccin
introduc
egypt
program
univers
immun
infanc
immunogen
short
medium
term
protect
efficaci
hepat
b
vaccin
well
document
howev
durat
protect
still
unknown
especi
antihb
declin
inadequ
undetect
level
studi
immun
respons
preschool
children
chang
serolog
anti
hb
obligatori
vaccin
seri
immun
respons
also
conduct
studi
evalu
effect
alt
ast
serum
albumin
antibodi
respons
hepat
b
surfac
antigen
nineti
select
primari
school
children
age
year
sex
receiv
hbv
vaccin
routin
immun
studi
efficaci
hb
vaccin
obtain
follow
result
seroprotect
rate
fulli
vaccin
children
mean
vaccin
children
protect
age
year
mean
antihb
vaccin
children
miuml
mean
alt
ul
signific
relationship
alt
hbsab
level
mean
ast
signific
relationship
ast
hbsab
level
mean
serum
albumin
gmdl
signific
relationship
albumin
hbsab
level
p
statist
signific
sex
hbsab
statist
signific
age
hbsab
necessari
give
booster
dose
school
entri
age
addit
recommend
need
give
dose
zero
reduc
risk
transmiss
viru
mother
fetu
stage
birth
vaccin
introduct
hcv
global
sequenc
classifi
genotyp
sever
subtyp
unassign
sequenc
aim
perform
depth
analysi
taxonom
relationship
unclassifi
strain
mean
phylogenet
analysi
materi
method
phylogenet
tree
reconstruct
perform
use
maximumlikelihood
method
use
fulllength
genom
partial
hcv
align
pdistanc
uncorrect
distanc
estim
complet
code
region
use
simpl
sequenc
editor
sse
softwar
assess
possibl
recombin
perform
use
recombin
detect
softwar
result
phylogenet
analysi
fulllength
sequenc
reveal
cluster
close
root
node
genotyp
show
distant
genet
relationship
previous
classifi
subtyp
unclassifi
sequenc
singl
section
analysi
use
sse
show
distanc
queri
subtyp
much
higher
distanc
within
subtyp
genotyp
p
phylogenet
analysi
includ
blast
hit
refer
sequenc
subtyp
show
strain
reveal
close
genet
relationship
sequenc
align
cluster
close
root
genotyp
recombin
analysi
reveal
evid
intersubtyp
genet
mix
queri
refer
differ
genotyp
subtyp
conclus
differ
analys
reveal
genet
diverg
within
genotyp
show
highor
lowlevel
cluster
previou
subtyp
unclassifi
sequenc
identif
singl
lineag
within
genotyp
without
late
branch
explain
genet
isol
late
stage
hcv
epidem
spread
analysi
bring
attent
uniqu
featur
use
current
state
art
phylogenet
genet
distanc
analys
effect
oral
direct
antivir
agent
chronic
hepat
c
viru
infect
hivhcv
coinfect
patient
success
stori
prospect
cohort
result
among
udi
hcv
genotypesubtyp
spread
follow
crf
patient
infect
one
genotyp
phylogenet
analysi
show
multipl
introduct
belaru
circul
counti
due
domest
spread
sequenc
select
differ
part
countri
form
cluster
separ
phylogenet
group
way
infect
particular
udi
differ
group
well
region
alloc
conclus
analysi
genotyp
distribut
hcv
udi
group
reveal
signific
differ
comparison
group
patient
find
suggest
genotyp
common
one
among
udi
among
group
patient
main
subtyp
patient
hcv
udi
sequenc
demonstr
phylogenet
cluster
use
develop
strategi
prevent
action
goal
reduc
spread
hcv
throughout
udi
well
epidemiolog
research
hepat
behavior
diseas
hcv
syphili
subafrica
affect
safeti
blood
recipi
studi
undertaken
aim
determin
seropreval
hiv
hbv
hcv
syphili
sociodemograph
risk
factor
associ
blood
donat
region
blood
transfus
center
togo
method
sera
sampl
screen
hepat
b
surfac
antigen
hbsag
antibodi
hcv
hiv
type
treponema
pallidum
use
enzym
link
immunosorb
assay
rapid
plasma
reagin
test
respect
rel
sampl
hiv
hbsag
hcv
confirm
use
second
enzymelink
immunosorb
assay
antibodi
treponema
pallidum
confirm
treponema
pallidum
haemagglutin
test
tpha
result
total
blood
donor
infect
least
one
pathogen
serolog
evid
multipl
infect
overal
seropreval
rate
hiv
hbv
hcv
syphili
respect
among
blood
donor
multipl
infect
common
dual
tripl
combin
hbsaghcv
hbsagsyphili
hbsaghcvsyphili
highest
preval
hbsag
hiv
found
among
blood
donor
rural
area
age
group
year
year
old
respect
conclus
hbv
hcv
remain
greatest
threat
blood
safeti
togo
strict
select
retent
voluntari
nonremuner
lowrisk
blood
donor
recommend
improv
blood
safeti
region
blood
transfus
center
treatment
result
great
high
cure
rate
expect
reach
least
cure
rate
averag
marp
end
project
time
abstract
develop
full
treatment
data
hcf
absent
henc
exclud
analysi
particip
educ
session
women
seen
cloth
abl
correctli
identifi
imageri
depict
particip
want
health
educ
session
avail
topic
includ
viral
infect
reproduct
children
health
nurs
prefer
sourc
health
relat
info
although
villag
chief
religi
leader
also
list
trust
sourc
conclus
vaccin
shown
desir
popul
educ
target
gender
prior
futur
vaccin
campaign
crucial
sinc
male
identifi
primari
decis
maker
expect
program
increas
hpv
vaccin
coverag
could
use
model
prior
introduct
hiv
vaccin
background
sever
acut
respiratori
syndrom
coronaviru
sarscov
outbreak
even
though
sarscov
remain
natur
bat
reservoir
still
reemerg
threat
vaccin
prophylact
strategi
diseas
control
prevent
antibodydepend
enhanc
ade
mechan
virus
dengu
viru
felin
coronaviru
hiv
altern
strategi
appli
infect
host
cell
gain
entri
target
cell
take
advantag
antivir
humor
immun
respons
ade
effect
sarscov
infect
controversi
materi
sarscov
strain
genbank
access
obtain
taiwan
cdc
sarscov
pseudotyp
viru
particl
harbor
sarscov
protein
hiv
core
structur
viru
construct
infect
assay
antisar
cov
infect
patient
sera
gener
monoclon
polyclon
antibodi
spike
protein
use
infect
neutral
assay
immunofluoresc
stain
transmiss
electron
microscopi
observ
perform
assay
viral
suscept
ade
hlcz
cell
sasrcov
infect
presenc
differ
dilut
antisera
sarscov
result
found
sarscov
use
ade
enhanc
infect
toward
human
promonocyt
cell
linehlcz
quantitativepcr
immunofluoresc
stain
indic
sarscov
replic
hlcz
display
virusinduc
cytopath
effect
well
increas
two
day
postinfect
result
flowcytometri
indic
hlcz
cell
express
angiotensin
convert
enzym
sarscov
receptor
higher
level
fcrrii
receptor
data
demonstr
higher
dilut
sera
sarscov
infect
patient
promot
sarscov
infect
induc
higher
level
apoptosi
infect
assay
demonstr
ade
sarscov
majorli
mediat
dilut
antibodi
envelop
spike
rather
nucleocapsid
protein
gener
monoclon
antibodi
spike
protein
sarscov
found
monoclon
antibodi
promot
sarscov
infect
conclus
suggest
antibodi
spike
protein
sarscov
may
caus
ade
effect
data
rais
reason
concern
regard
use
sarscov
vaccin
shed
light
role
sar
pathogenesi
sever
dengu
type
one
outbreak
taiwan
background
april
outbreak
denguelik
ill
occur
tuparetama
small
citi
northeast
region
brazil
outbreak
character
fast
expans
investig
initi
identifi
viral
etiolog
advis
health
author
implement
control
measur
contain
outbreak
first
report
outbreak
northeast
even
though
case
document
earlier
neighbor
citi
materi
method
plasma
sampl
obtain
suspect
dengu
patient
attend
main
hospit
citi
laboratori
assay
realtim
revers
transcript
polymeras
chain
reaction
rtpcr
viru
cdna
sequenc
enzymelink
immunosorb
assay
elisa
employ
identifi
infect
viru
molecular
phylogenet
analysi
perform
defin
circul
viral
genotyp
result
viral
nucleic
acid
igm
antibodi
detect
plasma
sampl
dengu
viru
denv
found
patient
zika
viru
zikv
found
patient
chikungunya
chikv
patient
coinfect
denv
zikv
detect
two
patient
phylogenet
analysi
two
avail
partial
denv
zik
sequenc
reveal
ident
genotyp
asiat
lineag
respect
conclus
consist
recent
report
region
result
show
ongo
outbreak
caus
zikv
denv
chikv
emphas
need
routin
differenti
diagnosi
arbovirus
patient
denguelik
ill
coordin
effort
necessari
contain
outbreak
continu
surveil
import
assess
effect
current
futur
prevent
strategi
gener
applic
monoclon
polyclon
antibodi
hemagglutinin
avian
influenza
viru
academia
sinica
institut
molecular
biolog
nankang
taipei
taiwan
new
avian
influenza
viru
emerg
transmit
human
sinc
human
infect
case
majorli
distribut
china
envelop
hemagglutinin
ha
interact
host
receptor
first
step
influenza
infect
target
antivir
agent
develop
baculoviru
produc
recombin
ha
rha
protein
prove
good
immunogen
induc
neutral
ab
monoclon
mab
polyclon
antibodi
poab
viral
neutral
capabl
use
applic
diseas
diagnos
immun
therapi
use
baculovirusinsect
system
express
protein
gener
four
mab
recognit
epitop
locat
globular
region
elisa
western
blot
result
indic
mab
poab
recogn
denatur
nativ
protein
flowcytometri
hi
indic
mab
poab
block
neutral
pseudotyp
rg
virus
bind
suscept
cell
attenu
viral
infect
gener
mab
poab
viral
neutral
capabl
could
use
immunotherapi
clinic
diagnos
futur
antivir
drug
target
select
avian
influenza
viru
comparison
modifi
acid
fast
stain
antigen
detect
assay
monoclon
antibodi
diagnosi
cryptosporidium
parvum
ibrahim
ali
rabab
zalat
gehan
elenain
eman
ali
theodor
bilharz
research
institut
cairo
egypt
cryptosporidiosi
common
worldwid
gastrointestin
diseas
anim
man
morbid
mortal
immunosuppress
patient
repercuss
infect
even
though
selflimit
immunocompet
host
mani
diagnost
techniqu
microscop
visual
immunofluoresc
pcr
use
detect
exist
intens
parasit
howev
still
insuffici
accur
result
studi
aim
compar
evalu
potenti
differ
diagnost
method
appli
stool
sampl
includ
direct
smear
formalinethyl
acet
sediment
concentr
mif
stain
techniqu
zn
elisa
latter
techniqu
parasit
intact
antigen
cryptosporidium
parvum
cyst
wall
detect
diarrhoea
use
specif
antimonoclon
antibodi
mab
research
conduct
total
patient
amongst
posit
demonstr
infect
cryptosporidium
use
direct
smear
mif
zn
respect
percentag
posit
highest
mab
addit
specif
assess
use
mab
found
compar
techniqu
result
obtain
work
use
mab
promis
tool
detect
cryptosporidium
parvum
cyst
stool
sampl
preval
congenit
cytomegaloviru
listeria
monocytogen
tehran
provinc
iran
nader
shahrokhi
talayeh
sey
shakeri
pasteur
institut
tehran
iran
introduct
newborn
diseas
transfer
mother
listeria
monocytogen
cytomegaloviru
preval
infecti
agent
transfer
mother
embryo
listeria
lead
prematur
birth
even
death
newborn
acut
condit
cmv
common
caus
congenit
infect
lead
abort
microorgan
cross
placenta
caus
clinic
sign
embryo
infant
henc
fast
detect
two
microorgan
especi
infanc
import
materi
method
infant
clinic
sign
week
refer
tehran
medic
center
suspect
infect
cytomegaloviru
listeria
monocytogen
oneyear
period
urin
serum
sampl
collect
urin
sampl
studi
presenc
dna
microorgan
use
pcr
method
presenc
cmvspecif
igm
igg
serum
sampl
test
accord
standard
procedur
result
infant
case
cmv
dna
case
listeria
monocytogen
dna
excret
urin
total
popul
studi
case
cmvigm
titer
excret
cmv
dna
urin
patient
cmvigg
antibodi
cmvdna
found
urin
case
cmv
dna
found
newborn
patient
clinic
sign
preterm
infant
respiratori
problem
seizur
common
symptom
result
show
serolog
marker
igm
igg
titer
adequ
especi
infant
may
sensit
specif
particular
molecular
detect
method
detect
viral
dna
pcr
effect
soon
first
day
also
find
shown
fast
accur
diagnosi
microorgan
symptomat
newborn
immedi
deliveri
necessari
treatment
prevent
post
infect
problem
new
gener
realtim
pcr
kit
human
leptospirosi
diagnosi
simian
plasma
score
cultureposit
human
pbmc
cell
line
indic
dual
tropism
lentivirus
transmiss
electron
micrograph
yield
evid
morpholog
reminisc
lentiviru
mitochondri
dna
analys
confirm
simian
speci
origin
crucial
amplif
alultr
repeat
confirm
proviru
integr
monkey
genom
result
despit
low
viral
load
qrtpcr
sequenc
gene
viral
genom
region
reveal
unexpect
homolog
north
indian
subtyp
b
rather
known
siv
analys
nef
vif
partial
env
sequenc
reveal
sever
polymorph
vif
nef
sequenc
truncat
like
caus
low
viral
load
spri
domain
alpha
wild
rhesu
monkey
ident
captiv
rhesu
macaqu
conclus
instead
bona
fide
macaqu
langur
lentiviru
data
suggest
revers
transmiss
subtyp
b
human
simian
like
due
aggress
monkey
bite
follow
adapt
simian
novel
lentivirus
potenti
use
import
cell
base
model
investig
infect
pathogenesi
cost
treat
tuberculosi
patient
famili
result
inform
concern
incom
reduct
budget
patient
famili
carri
treatment
monthli
individu
incom
decreas
incom
treatment
report
decreas
attribut
tb
respect
famili
incom
incom
greater
us
case
decreas
incom
reduc
reduct
attribut
tb
unemploy
time
interview
case
reason
ill
median
direct
cost
patient
us
indirect
cost
patient
famili
result
total
cost
us
conclus
addit
cost
impact
budget
patient
famili
high
tb
treatment
factor
consid
develop
diseas
control
strategi
econom
analysi
tuberculosi
control
program
difficulti
found
real
situat
health
technolog
caus
concern
among
manag
tend
incur
high
cost
lack
knowledg
cost
effect
health
meant
econom
assess
studi
becom
essenti
object
describ
difficulti
applic
method
analysi
cost
real
situat
within
tuberculosi
control
program
tcp
citi
preto
state
paulo
brazil
method
exploratori
descript
epidemiolog
studi
base
survey
data
collect
data
collect
medic
file
interview
health
profession
tcp
estim
direct
medic
cost
interview
patient
tuberculosi
tb
estim
indirect
direct
nonmed
cost
result
sever
variabl
note
hinder
operation
studi
data
collect
medic
file
interview
patient
health
profession
difficulti
factor
observ
includ
structur
organ
tcp
insuffici
physic
infrastructur
human
resourc
inform
deficit
lack
data
relat
cost
tb
treatment
b
health
profession
difficulti
relat
collabor
investig
accept
carri
field
research
work
overload
medic
form
fill
incorrectli
c
locat
patient
home
difficult
access
high
risk
area
drug
traffick
patient
absenc
patient
home
interview
carri
weekend
holiday
failur
attend
doctor
visit
health
servic
depart
lack
commun
admiss
hospit
institut
drug
abus
treatment
prison
system
conclus
great
challeng
carri
research
assess
health
technolog
brazil
due
low
qualiti
data
registri
inform
directli
observ
treatment
tuberculosi
direct
medic
cost
brazilian
health
system
tuberculosi
tb
common
preval
brazil
estim
cost
use
due
need
carri
research
relat
econom
assess
brazilian
health
system
object
estim
direct
medic
cost
treatment
tb
public
health
system
address
strategi
directli
observ
treatment
dot
selfmanag
treatment
smt
method
descript
epidemiolog
analyt
studi
base
survey
cost
estim
conveni
sampl
includ
patient
regist
period
health
center
preto
medic
school
univers
paulo
usp
brazil
data
obtain
medic
file
medic
exam
visit
b
interview
health
profession
tuberculosi
control
program
tcp
physician
nurs
nurs
assist
c
interview
profession
monitor
medic
use
patient
home
driver
sanitari
visitor
includ
resourc
use
make
feasibl
visit
dot
fuel
result
tabl
show
distribut
cost
treatment
strategi
dot
smt
patient
dot
strategi
result
averag
cost
us
smt
strategi
us
sinc
begin
treatment
followup
diseas
discharg
rate
treatment
interrupt
patient
dot
situat
similar
rate
patient
smt
situat
respect
estim
ratio
cost
end
treatmentcur
us
treat
one
case
dot
strategi
us
treat
one
case
smt
strategi
conclus
monitor
intak
tb
medic
carri
patient
home
dot
strategi
gener
high
cost
health
system
howev
whether
treatment
strategi
costeffect
depend
addit
studi
health
technolog
assess
